Head-to-head · WeighScore
MANÜ Telehealth vs MyStart Health
The verdict
MANÜ Telehealth takes it — 72.2/100 to 67.1/100.
MANÜ Telehealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MANÜ Telehealth is a US online platform offering compounded GLP-1 weight loss medication including injectable tirzepatide and semaglutide, with add-ons like MIC Ultraburn and NAD+ injections.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | MANÜ Telehealth | MyStart Health |
|---|---|---|
| WeighScore | 72.2/100 | 67.1/100 |
| Grade | C | C |
| Scorecard rank | #83 | #168 |
| Semaglutide | $120/mo (compounded) | $299/mo (all doses, compounded) |
| Tirzepatide | $150/mo (compounded) | $299/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #83 · C
Strengths
- Compounded GLP-1s advertised from about $4-$5/day
- 100% online with free discreet shipping and no insurance needed
- Compounds exclusively from US 503A pharmacies
- Add-on options like MIC Ultraburn and NAD+
Where it loses points
- Per-dose pricing is gated behind login/signup, not public
- State availability changes and is only confirmed at signup
- Compounded medications are not FDA-evaluated
Graded #168 · C
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
Where it loses points
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- Pharmacy partners not named, so 503A compliance can't be independently verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.